SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jongmans who started this subject9/8/2004 5:01:39 AM
From: nigel bates  Read Replies (1) of 625
 
New Drug Candidate for Severe Asthma From Cambridge Antibody Technology Starts Clinical Trials
Wednesday September 8, 2:00 am ET

CAMBRIDGE, UK, Sept. 8 /PRNewswire-FirstCall/ -- Cambridge Antibody Technology (LSE: CAT - News; Nasdaq: CATG - News) today announces that it will be starting a Phase I clinical trial of CAT-354, a human anti-IL-13 monoclonal antibody, which is a potential treatment for severe asthma, following recent approval from the Medicines and Healthcare products Regulatory Agency (MHRA).

The Phase I trial is a placebo-controlled, rising single intravenous dose study of CAT-354 and will take place in the UK at the Marix Drug Development Clinical Research Centre, Llantrisant, South Wales. The objectives of the trial will be to study the safety, tolerability and pharmacokinetics of CAT- 354. Patient enrolment is expected to commence shortly and the results of the trial are likely to be available during the second quarter of 2005.

Dr. David Glover, CAT's Chief Medical Officer, comments: "The initiation of this clinical trial represents a further milestone in the development of CAT as a biopharmaceutical company. CAT-354 is the fourth human monoclonal antibody that we have taken into clinical trials ourselves and makes a total of 11 human antibody drug candidates discovered using our technology that have entered clinical development. We are very optimistic about CAT-354 as a potential treatment for severe asthma." ...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News